RNAM Avidity Biosciences Inc
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
6.44
P/S
600.12
EV/EBITDA
-14.79
DCF Value
$-4.03
FCF Yield
-5.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
77.9%
Operating Margin
-3977.3%
Net Margin
-3650.4%
ROE
-44.9%
ROA
-35.0%
ROIC
-42.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 null | $860.0K | $-237.1M | $— |
| FY null | $18.8M | $-684.6M | $— |
| Q3 null | $12.5M | $-174.4M | $— |
| Q2 null | $3.8M | $-157.3M | $— |
Analyst Ratings
View AllConsensus
Hold
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.93
Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.